HEMATOPOIESIS - BRIEF REPORT Phase I Clinical Study of Eltrombopag, an Oral, Non-peptide Thrombopoietin Receptor Agonist
نویسندگان
چکیده
1. All of the authors (JMJ, DW, YD, JU, VK, DC, CEM) have declared a financial interest in a company whose (potential) product was studied in the present work. 2. Several of the authors (CEM, DC )have declared a financial interest in a competitor of a company whose (potential) product was studied in the present work. 3. All of the authors (JMJ, DW, YD, JU, VK, DC, CEM) are employed by a company or a competitor of a company (X company) whose (potential) product was studied in the present work. 4. Several of the authors (JMJ, CEM) hold a patent related to the work that is described in the present study.
منابع مشابه
The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia
Severe aplastic anemia (SAA) has an aggressive clinical course and represents a “difficult-to-treat” situation with current medications [1]. Eltrombopag is a c-mpl receptor agonist oral thrombopoietin-mimetic drug, mainly active in immune thrombocytopenic purpura (ITP) [2]. Single-agent oral eltrombopag produced hematological responses in 11 of 25 cases of aplastic pancytopenia, with trilineage...
متن کاملEffect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
Thrombocytopenia is a frequent symptom and clinical challenge in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Eltrombopag is a small molecule thrombopoietin receptor agonist that might be a new option to treat thrombocytopenia in these diseases, provided that it does not stimulate malignant hematopoiesis. In this work, we studied the effects of Eltrombopag on p...
متن کاملEltrombopag--an oral thrombopoietin agonist.
The therapy for immune thrombocytopenic purpura (ITP) has evolved in the recent past. In certain cases therapy for ITP remains inadequate. Thrombopoietin receptor agonists are the latest addition to the armamentarium to manage the thrombocytopenia. While romiplostim was the first second generation thrombopoietin agonist to become available, eltrombopag is particularly attractive as it is an ora...
متن کاملThe non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma
BACKGROUND Thrombocytopenia is a significant problem in patients with relapsed or refractory multiple myeloma, precipitating a need for supportive platelet transfusions and necessitating decreases in delivered doses of chemotherapy. Eltrombopag is a non-peptide, small molecule thrombopoietin (TPO) receptor agonist that promotes megakaryopoiesis similar to endogenous human TPO and may be an effe...
متن کاملPreclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist
Eltrombopag is a first-in-class, orally bioavailable, small-molecule, nonpeptide agonist of the thrombopoietin receptor (TpoR), which is being developed as a treatment for thrombocytopenia of various etiologies. In vitro studies have demonstrated that the activity of eltrombopag is dependent on expression of TpoR, which activates the signaling transducers and activators of transcription (STAT) ...
متن کامل